SH-1028 Tablets Versus Placebo as Adjuvant Therapy in Resected Stage II-IIIB NSCLC With Sensitizing EGFR Mutations

This study tests whether a targeted pill called SH-1028 can help prevent lung cancer from coming back after surgery in patients whose tumors have a specific genetic mutation (EGFR). It compares the pill to a placebo (sugar pill) taken daily after surgery. **You may be eligible if...** - You are 18 to 74 years old - You had surgery to completely remove non-small cell lung cancer (a specific type) - Your cancer was stage II, IIIA, or a specific form of IIIB after surgery - Your tumor has a specific EGFR gene mutation (a genetic change that makes the cancer sensitive to certain drugs) - You have recovered well from surgery - Your blood tests show your organs are functioning adequately **You may NOT be eligible if...** - Your cancer could not be fully removed or has spread - You have previously received certain cancer treatments including EGFR-targeted drugs, chemotherapy, or immunotherapy after surgery - You have serious heart conditions, severe liver disease, or uncontrolled infections - You have a history of a specific type of lung scarring (interstitial lung disease) - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.